Drug intelligence / Profile preview

MTX110 + gadolinium

Development stage: Unknown
Lead developer: Biodexa Pharmaceuticals
Modality: Small Molecules
Administration: Intratumoral

Overview

MTX110 + gadolinium is a combination therapy administered via convection-enhanced delivery (CED) directly to brain tumors. MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl-β-cyclodextrin (HPBCD). Gadolinium is included as a contrast agent that helps visualize abnormal areas in the brain during treatment. The combination is designed to bypass the blood-brain barrier, allowing for higher drug concentrations at the tumor site while limiting systemic exposure and potential side effects.

Targets

TXNRD1 (Thioredoxin reductase 1)

Beyond the preview

Go deeper on MTX110 + gadolinium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTX110 + gadolinium.

Explore the full profile